Teva Pharmaceutical Industries Ltd. (TEVA) announced it has entered into a settlement agreement with Wyeth (WYE)/Pfizer (PFE) and Altana (AAAGY.PK)/Nycomed to resolve all claims relating to Teva's sales, commencing in December 2007, of its 20 mg and 40 mg generic Protonix tablets. Teva has agreed to pay $1.6 billion to Wyeth/Pfizer and Altana/Nycomed for the settlement of the patent infringement case.
Teva will pay $800 million in 2013 and the remainder in 2014. As a result of the settlement, Teva expects to incur a charge of approximately $930 million in the second quarter of 2013.
Teva believes it may have up to $560 million of net insurance coverage in connection with this settlement, subject to recovery from the insurance carriers.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.